For more than 50 years, Roche has been developing innovative diagnostics and therapies with the goal to transform cancer care. Greater understanding of cancer biology combined with technological advancements allows us to deliver industry-leading diagnostics.
Progress in cancer treatment has been made through molecular analysis and biomarker discovery. Major breakthroughs have transformed several aspects of screening strategies and clinician care for treatment decisions. Cancer treatment has evolved from broad chemotherapy to targeted therapy and immunotherapies. Additionally, innovative technologies such as next-generation sequencing, liquid biopsies and artificial intelligence powered image analysis algorithms are facilitating an evolution in personalised healthcare. These advances have changed the natural course of disease for millions of patients.
Our long-term vision is to help prevent or cure this disease in all its forms, and our scientific rigor, pipeline of innovative therapies and our passion for progress will continue to aid in the advancement of cancer care in the years ahead.
15 December 2020
Roche launches cobas® PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark.
